By Denise Mueller, Chief Business Officer, Affimed
The world of work is more uncertain than ever and the biotechnology sector is no exception, especially as we see ongoing fluctuations in the market and shifting preferences among investors and potential business development partners.
Our industry is still slowly coming back from an industrywide plummeting of the IPO market in 2021. While were seeing recovery in some areas like the autoimmune space, emerging organizations in biotech now face a much tougher path not to mention facing tougher questions around platform technology and product differentiation.
More than ever, we need to consider measured growth strategies to help ensure that investments lead to the generatio…
Read the full article at: https://www.lifescienceleader.com/doc/biotech-restructuring-leading-through-ambiguity-0001